Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
83.9 EUR | +1.64% |
|
-2.83% | -19.85% |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.57 for the current year.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.85% | 6.63B | - | ||
+1.62% | 101B | A- | ||
-11.50% | 59.18B | A- | ||
+71.43% | 47.51B | B | ||
+4.53% | 34.67B | B | ||
-0.16% | 30.91B | A- | ||
+1.99% | 18.35B | B- | ||
+18.42% | 17.59B | - | C+ | |
+5.32% | 13.43B | B- | ||
-7.05% | 12.67B | - | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AKE Stock
- V1S Stock
- Ratings Arkema